$8.23
+0.73%CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Last Annual Value
99.10M
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
| Company | Other Non-Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() CorMedix Inc. NASDAQ:CRMD | 99.10M | N/A | N/A | N/A | |
![]() ProKidney Corp. NASDAQ:PROK | 1.07M | 23.7% | N/A | N/A | |
![]() Kura Oncology, Inc. NASDAQ:KURA | 3.16M | 65.0% | 53.2% | 34.0% | |
![]() EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT | 87.00K | N/A | -48.3% | 5.5% | |
![]() Savara Inc. NASDAQ:SVRA | 0.00 | N/A | N/A | N/A | |
![]() Tango Therapeutics, Inc. NASDAQ:TNGX | 0.00 | N/A | N/A | N/A | |
![]() Septerna, Inc. NASDAQ:SEPN | 105.92M | -10.9% | N/A | N/A | |
![]() Arbutus Biopharma Corporation NASDAQ:ABUS | 8.39M | 3.4% | 9.6% | -16.4% | |
![]() Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX | 0.00 | N/A | N/A | N/A | |
![]() Palvella Therapeutics, Inc. NASDAQ:PVLA | 19.80M | 29.7% | N/A | N/A |
Continue your CRMD research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.